-
Use of Bortezomib in the management of chronic graft versus host disease among multiple myeloma patients relapsing after allogeneic transplantation Mateos-Mazón J, Pérez-Simón JA, López O, Hernández E, Etxebarria J, San Miguel JF Haematologica 92(9):1295-6 FI: 6.416 (Q1) 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, Garcia-Sanz R, Moro MJ, Aguilera C, Hernandez J, Xu R, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalez-Paz N, Gertz MA, San Miguel JF, Fonseca R British Journal of Haematology 136(1):80-6 FI: 4.597 (Q1)
-
A practical update on the use of bortezomib in the management of multiple myeloma. San Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. Oncologist 11(1):51-61. FI: 6.701 (Q1) Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma Martínez-López J, Martínez-Sánchez P, García-Sanz R, Sarasquete ME, Ayala R, González M, San Miguel JF, García-Effron G, Lahuerta JJ Journal of Molecular Diagnostics 8(3):364-70 FI: 3.413 (Q1) Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E, Schenkein D, Pandiella A, San Miguel JF Blood 107(9):3575-83 FI: 10.555 (Q1) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Blood 108(7):2165-72 FI: 10.555 (Q1) Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Pérez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nuñez G, Galende J, Hernandez J, Mateo G, San Miguel JF, Orfao A, Spanish Network on Multiple Myeloma, Spanish Network of Cancer Research Centers Cancer 106(6):1296-305. FI: 5.418 (Q1) Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel JF, Orfao A. Leukemia & Lymphoma 47(1):29-37. FI: 2.397 (Q3) Conventional diagnostics in multiple myeloma San Miguel JF, Gutiérrez NC, Mateo G, Orfao A European Journal of Cancer 42(11):1510-9 FI: 4.121 (Q2) Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM study) de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel JF Haematologica 91(5):621-7 FI: 6.416 (Q1)
|
